Table SII. *Summary of clinical parameters±cutaneous adverse reaction (CAR)*

	All patients ($n=26$)			Patients who received ≥4 cycles of mogamulizumab ($n=18$)		
Characteristics and outcome	CAR (+) ($n=7$)	CAR (–) ($n=19$)	p	CAR (+) ($n=7$)	CAR (–) ($n=11$)	p
Age, median (range)	62 (57–83)	68 (55–79)	0.86	62 (57–83)	68 (55–79)	0.65
Sex, *n*						
Male	2	12	0.19	2	6	0.37
Female	5	7		5	5	
Treatment cycles of mogamulizumab, median (range)	7 (4–8)	4 (1–8)	0.06	7 (4–8)	4 (4–8)	0.67
Previous treatment regimens, *n*, median (range)	2 (0–4)	1 (1–7)	0.75	2 (0–4)	1 (1–7)	0.96
Lactate dehydrogenase at the start of mogamulizumab treatment, median (range)	339 (265–458)	431 (150–2011)	0.33	339 (265–458)	409 (185–797)	0.79
sIL-2R at the start of mogamulizumab treatment, median (range)	6,586 (1,640–37,644)	7,744 (1,789–55,400)	0.69	6,586 (1,640–37,644)	7,382 (2,160–55,400)	0.72
Best response to mogamulizumab treatment, *n*						
Complete remission+partial remission	6	7	0.07	6	5	0.15
Stable disease+Progressive disease	1	12		1	6	